Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

Gray, Jhanelle; Villegas, Augusto; Daniel, Davey; Vicente, David; Murakami, Shuji; Hui, Rina; Kurata, Takayasu; Chiappori, Alberto; Lee, Ki; Cho, Byoung; Planchard, David; Paz-Ares, Luis; Faivre-Finn, Corinne; Vansteenkiste, Johan; Spigel, David; Wadsworth, Catherine; Taboada, Maria; Dennis, Phillip; Ozguroglu, MUSTAFA; Antonia, Scott

doi:10.1016/j.jtho.2019.10.002

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

Gray J. E., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.15, sa.2, ss.288-293, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 15 Sayı: 2
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.jtho.2019.10.002
Dergi Adı: JOURNAL OF THORACIC ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.288-293
Anahtar Kelimeler: Durvalumab, NSCLC, Overall survival, PACIFIC, Three-year update
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Introduction: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42-65, p < 0.0001) and overall survival (OS) (HR = 0.68, 95% CI: 0.53-0.87, p = 0.00251), with manageable safety and no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study.